Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)

Y. Antill, P. S. Kok, M. R. Stockler, K. Robledo, S. Yip, M. Parry, D. Smith, A. Spurdle, E. Barnes, M. L. Friedlander, S. Baron-Hay, C. Shannon, J. Coward, J. Beale, G. Goss, T. Meniawy, J. Andrews, M. Kelly, L. Mileshkin

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume30
Publication statusPublished - Nov 2019
Externally publishedYes
EventEuropean-Society-for-Medical-Oncology (ESMO) Asia Congress - Singapore, Singapore
Duration: 22 Nov 201924 Nov 2019

Cite this

Antill, Y., Kok, P. S., Stockler, M. R., Robledo, K., Yip, S., Parry, M., Smith, D., Spurdle, A., Barnes, E., Friedlander, M. L., Baron-Hay, S., Shannon, C., Coward, J., Beale, J., Goss, G., Meniawy, T., Andrews, J., Kelly, M., & Mileshkin, L. (2019). Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). Annals of Oncology, 30.